Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Cook Medical Makes Progress In Peripheral Stent Space

This article was originally published in The Gray Sheet

Executive Summary

Cook Medical is making advances in the peripheral stent market with the imminent launch of its Formula balloon-expandable renal stent system, and a recent report of two-year data for its PMA-pending Zilver PTX paclitaxel-eluting stent.

You may also be interested in...



Cook’s Zilver PTX Peripheral Drug-Eluting Stent Sails Through FDA Panel

Cook Medical’s first-of-a-kind Zilver PTX percutaneous paclitaxel-eluting peripheral stent received unanimous and enthusiastic support from the FDA’s Circulatory System Devices panel last week.

Cook’s Zilver PTX Peripheral Drug-Eluting Stent Sails Through FDA Panel

Cook Medical’s first-of-a-kind Zilver PTX percutaneous paclitaxel-eluting peripheral stent received unanimous and enthusiastic support from the FDA’s Circulatory System Devices panel last week.

Regulatory News In Brief

Cook’s Zilver PTX stent goes to panel

Related Content

UsernamePublicRestriction

Register

MT029776

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel